Status:
COMPLETED
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
Lead Sponsor:
R-Pharm
Conditions:
Breast Cancer
Metastases
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
- No more than 3 prior chemotherapy regimens in the metastatic setting
- Must have at least one target lesion that is radiographically measurable
- Good performance status
- No history of or current brain or leptomeningeal disease
Exclusion
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00080262
Start Date
February 1 2004
End Date
December 1 2006
Last Update
January 30 2017
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
La Verne, California, United States
2
Local Institution
Meriden, Connecticut, United States
3
Local Institution
Jacksonville, Florida, United States
4
Local Institution
Baltimore, Maryland, United States